Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera

A R Moliterno1, J L Spivak

  • 1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Blood
|October 9, 1999
PubMed

Insights

Polycythemia vera (PV) platelets show reduced thrombopoietin receptor (Mpl) expression with two abnormal Mpl isoforms. This indicates a specific Mpl glycosylation defect in PV megakaryocytes, correlating with disease progression.

Area of Science:

  • Hematology
  • Molecular Biology
  • Protein Biochemistry

Background:

  • Thrombopoietin receptor (Mpl) expression is reduced in polycythemia vera (PV) platelets and megakaryocytes.
  • Previous studies utilized antisera against the Mpl extracellular domain to demonstrate this reduction.
  • Further investigation is needed to characterize the molecular nature of Mpl in PV.

Purpose of the Study:

  • To investigate the molecular characteristics of Mpl in PV platelets.
  • To identify potential abnormalities in Mpl processing and glycosylation in PV.
  • To correlate Mpl abnormalities with disease parameters in PV.

Main Methods:

  • Raised an antibody to the Mpl C-terminus for immunologic analysis.
  • Performed two-dimensional gel electrophoresis with isoelectric focusing.
  • Utilized neuraminidase and endoglycosidase H digestion to analyze Mpl glycosylation and processing.

Main Results:

  • PV platelets express two Mpl isoforms (85-92 kD, pI 5.5 and 80-82 kD, pI 6.5), unlike normal platelets (single form).
  • Neuraminidase treatment interconverted Mpl isoforms, indicating differences in posttranslational glycosylation.
  • PV Mpl was susceptible to endoglycosidase H, suggesting defective Mpl processing in PV megakaryocytes, while other glycoproteins were unaffected.

Conclusions:

  • PV platelets exhibit abnormal Mpl isoforms due to defective posttranslational glycosylation.
  • This specific Mpl glycosylation defect in PV megakaryocytes correlates with disease duration and extramedullary hematopoiesis.
  • The findings highlight a novel molecular abnormality in PV pathogenesis.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.